# Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Source: https://onco.cc/trials/nct03876769/  
OnCo record `nct03876769` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tisagenlecleucel in acute lymphoblastic leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients is a phase 2 interventional study registered as NCT03876769 by Novartis Pharmaceuticals, with 121 participants enrolled, started 2019-06-24 and due to reach its primary completion in 2027-10-19. Interventions recorded: CTL019.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03876769
- Phase: 2
- Setting: A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 121

## Sources

- ClinicalTrials.gov NCT03876769: https://clinicaltrials.gov/study/NCT03876769

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [Tisagenlecleucel](https://onco.cc/drugs/tisagenlecleucel/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct03876769.json